Novartis AG (NVS) EPS Estimated At $1.31

June 14, 2018 - By Tina Thibodeau

Novartis AG (NYSE:NVS) Logo

Analysts expect Novartis AG (NYSE:NVS) to report $1.31 EPS on July, 17.They anticipate $0.10 EPS change or 8.26 % from last quarter’s $1.21 EPS. NVS’s profit would be $3.34B giving it 14.50 P/E if the $1.31 EPS is correct. After having $1.28 EPS previously, Novartis AG’s analysts see 2.34 % EPS growth. The stock increased 0.25% or $0.19 during the last trading session, reaching $75.98. About 1.30M shares traded. Novartis AG (NYSE:NVS) has declined 6.45% since June 14, 2017 and is downtrending. It has underperformed by 19.02% the S&P500.

Novartis AG (NYSE:NVS) Ratings Coverage

Among 4 analysts covering Novartis (NYSE:NVS), 0 have Buy rating, 0 Sell and 4 Hold. Therefore 0 are positive. Novartis had 4 analyst reports since January 25, 2018 according to SRatingsIntel. The company was maintained on Friday, February 2 by Cowen & Co. The firm has “Neutral” rating by Credit Suisse given on Friday, May 25. The rating was maintained by Leerink Swann with “Market Perform” on Thursday, January 25. The rating was downgraded by HSBC to “Hold” on Tuesday, May 29.

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company has market cap of $193.56 billion. The companyÂ’s Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. It has a 23.38 P/E ratio. This divisions also franchises ophthalmology, neuroscience, immunology and dermatology, respiratory, cardio-metabolic, and other medicines, as well as cell and gene therapies.

More notable recent Novartis AG (NYSE:NVS) news were published by: Seekingalpha.com which released: “Novartis: Exit Sandoz US Now” on June 06, 2018, also Seekingalpha.com with their article: “Intercept And Obeticholic Acid Therapy: Discerning Scientific Facts From Fallacies On Cholestatic Liver Diseases” published on June 12, 2018, Fool.com published: “Should CRISPR Stock Investors Worry About Cancer?” on June 13, 2018. More interesting news about Novartis AG (NYSE:NVS) were released by: Seekingalpha.com and their article: “Novartis lawyer out amid Cohen payments” published on May 16, 2018 as well as Seekingalpha.com‘s news article titled: “Veeva Systems: Expanding Its Growth Runway Ahead” with publication date: June 08, 2018.

Novartis AG (NYSE:NVS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.